… , the combination of BRAF and TERT promoter mutations stratifies PTC aggressiveness into
distinct subgroups in which the PTCs with concurrent BRAF and TERT promoter mutations …

… In summary, this study demonstrates the transcriptional and mutational landscape of miFTC
and FA together with cPTC and FVPTC. We revealed that thyroid cancers developed by …

Importance BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid cancer
(PTC). This genetic duet was indicated to be involved in the aggressiveness of PTC, but its …

… Hashimoto's thyroiditis and BRAF V600E mutation status in patients with papillary thyroid
cancer (PTC) and to determine their combined association with tumor aggressiveness in PTC. …

… In the present study, approximately 40% of multifocal PTCs cases had mixed BRAF V600E
mutational status, which supports the notion that a large percentage of multifocal PTCs are …

… Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in
BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent …

… Despite its potential clinical impact, intra-tumor genetic heterogeneity (ITH) has been scantly
investigated in papillary thyroid cancer (PTC). We studied ITH in PTC by combining, for the …

… , represents a recombinant protein product of a chromosomal rearrangement with the
combination of the 3′ portion of the RET gene and the 5′ portion of an unrelated gene (27, 28). …

… Our results show that the BRAF V599E mutation is almost exclusively seen in PTC with a
conventional (papillary or mixed follicular–papillary) pattern of growth and is particularly …

… The optimal method for BRAF mutation detection remains to be determined … 15 mutations
were searched in formalin-fixed paraffin-embedded tissues from 86 papillary thyroid carcinoma …